A

Alzheimer Drugs (ALZ)
HRC Report, Update #1 - 10/06

Analgesics/Anesthetics, Topical
OHA PDL Source Document - 4/10

Androgenic Agents
OHA PDL Source Document - 12/09

Angiotensin II Receptor Antagonists (AIIRA)
HRC Report - 3/06  |  Clinician Summary - 3/06

Angiotensin-Converting Enzyme Inhibitors (ACEIs)
HRC Report, Update #2 - 7/05

Antibiotics, Ophthalmic
OHA PDL Source Document - 12/09

Antibiotics, Otic
OHA PDL Source Document - 12/09

Antibiotics, Topical
OHA PDL Source Document - 3/10

Antibiotic-Steroid Combinations, Ophthalmic
OHA PDL Source Document - 3/10

Anticoagulants, Injectable
OHA PDL Source Document - 12/09

Anticonvulsants
OHA PDL Source Document - 12/09

Antidepressants, Second Generation
HRC Draft Report, Update #4 - 1/09  |  Clinician Summary - 6/11

Antiemetics (NAE)
HRC Report - 5/06

Anti-epileptics
Clinician Summary - 6/11

Antifungals, Oral
OHA PDL Source Document - 1/10

Antifungals, Topical
OHA PDL Source Document - 2/10

Antihyperuricemics
OHA PDL Source Document - 5/10

Anti-Inflammatories Ophthalmic
OHA PDL Source Document - 12/09

Antiparasitic Agents, Topical
OHA PDL Source Document - 12/09

Antiparkinson's Agents
OHA PDL Source Document - 3/10

Antiplatelet (AP)
HRC Report, Update #1 - 4/07  |  Clinician Summary - 3/06

Antivirals for HSV
OHA PDL Source Document - 1/10

Antivirals for Influenza
OHA PDL Source Document - 4/10

Asthma, Controller Medications
HRC Report - 9/09  |  Clinician Summary - 12/09

Asthma, Quick Relief Medicines
Clinician Summary - 6/11

Attention Deficit Hyperactivity Disorder (ADHD)
HRC Report - 6/08

Atypical Antipsychotics
HRC Draft Report - 12/10  |  Clinician Summary - 3/11

B

Beta 2-Agonists (B2)
HRC Report - 11/07

Beta Blockers (BB)
HRC Draft Report, Update # 3 - 3/08  |  Clinician Summary - 9/05

Bone Resorption
OHA PDL Source Document - 1/10

BPH Treatment
OHA PDL Source Document - 3/10

Bronchodilators, Anticholinergic
OHA PDL Source Document - 1/10

C

Calcium Channel Blockers (CCB)
HRC Report, Update # 2 - 5/05  |  Clinician Summary - 9/05

Cephalosporins and Related Antibiotics
OHA PDL Source Document - 3/10

Combination Drug Products (FDCP) for Type 2 Diabetes & Hyperlipidemia
HRC Report - 4/08

Constipation Drugs
HRC Draft Report - 12/08

Cough and Cold
OHA PDL Source Document - 5/10

D

Diabetes Mellitus, Newer Drugs for
HRC Draft Report - 6/09

Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, & Angiotensin II Receptor Blockers
HRC Draft Report - 1/10

E

Erythropoiesis Stimulating Proteins
OHA PDL Source Document - 3/10

F

Fluoroquinolones, Oral
OHA PDL Source Document - 11/09

G

Glaucoma Agents, Ophthalmics
OHA PDL Source Document - 10/09

Growth Hormone
OHA PDL Source Document - 4/10

H

Hepatitis B Agents
OHA PDL Source Document - 11/09

Histamine 2 Receptor Antagonists
OHA PDL Source Document - 2/10

Hormone Replacement Therapy (HRT)
HRC Report, Update #3 - 4/08  |  Clinician Summary - 6/05

H. pylori Treatment
OHA PDL Source Document - 1/10

I

Immunosuppressants
OHA PDL Source Document - 4/10

Inhaled Corticosteroid (ICS)
HRC Report, Update #1 - 1/06  |  Clinician Summary - 4/06

Insomnia, Newer Drugs for
Clinician Summary - 6/11

Insulins
OHA PDL Source Document - 3/10

L

Long-acting Analgesics for Non-cancer Pain (OPIOID)
HRC Report, Update #2 - 5/05  |  Clinician Summary - 6/05

M

Macrolides - Ketolides
OHA PDL Source Document - 3/10

Multiple Sclerosis (MS)
HRC Report - 5/08  |  Clinician Summary - 6/11

N

Narcotic Analgesics, Short Acting
OHA PDL Source Document - 3/10

Neuropathic Pain
HRC Draft Report - 3/08  |  Clinician Summary - 6/11

Newer Antiplatelet Agents(AP)
HRC Report, Update #1 - 4/07

Non-steroidal Anti-inflammatory Drugs (NSAIDS)
HRC Draft Report, Update #3 - 2/07  |  Clinician Summary - 6/05

O

Obesity, Medical Management of
HRC Report - 6/07

Oncology Agents, Oral Review
OHA PDL Source Document - 5/10

Oral Hypoglycemics (OH)
HRC Report, Update #2 - 5/05  |  Clinician Summary - 6/05

Over Active Bladder (OAB), Agents for
HRC Report, Update #3 - 3/06  |  Clinician Summary - 4/06

P

Pancreatic Enzymes
OHA PDL Source Document - 3/10

Peginterferons for Hepatitis C
HRC Report - 9/07

Phosphate Binders
OHA PDL Source Document - 12/09

Proton Pump Inhibitors (PPI)
HRC Report, Update #4 - 7/06  |  Clinician Summary - 9/05  |  Clinician Summary - 6/11

Psoriasis, Topical
OHA PDL Source Document - 1/10

Pulmonary Arterial Hypertension (PAH) Agents
OHA PDL Source Document - 12/09

S

Skeletal Muscle Relaxers (SMR)
HRC Report, Update #2 - 5/05  |  Clinician Summary - 6/05

Statin
HRC Report, Update #5 - 2/10  |  Clinician Summary - 4/06

T

Targeted Immune Modulators (TIM)
HRC Draft Report - 12/09  |  Clinician Summary - 8/05

Tetracyclines
OHA PDL Source Document - 2/10

Thrombopoeisis Stimulating Proteins
OHA PDL Source Document - 12/09

Triptans
HRC Draft Report - 3/10  |  Clinician Summary - 4/06

U

Ulcerative Colitis Agents
OHA PDL Source Document - 4/10